April 23-25, 2019
Amsterdam

 

Day One
WEDNESDAY, 24TH APRIL 2019

Day Two
Thursday, 25TH APRIL 2019

08.00
Coffee & Networking

08.45
Chair’s Opening Remarks

Driving the Prioritsation & Characterisation of Neoantigens

09.00
One for All & All for One – Bioengineering of T cells with Specificity for Neoantigens in Solid Tumours

Synopsis

  • Targeting of solid tumours based on the identification and prioritisation of neoantigens
  • Targeting of neoantigens based on the identification and prioritisation of T-cell receptors (TCRs)
  • Using Sleeping Beauty system to express neoantigen-specific TCRs in clinical grade T cells

09.30
Identification of Relevant Antigenic Targets for Successful Liver Cancer

Synopsis

  • Background on Hepatocellular Carcinoma and how the liver microenvironment affects the immune cells
  • Relevant examples of successful/promising immunotherapies in hepatocellular carcinoma patients (cytokines, mAbs, TILs, CARs)
  • Our hypothesis: successful immunotherapy depends on targeting the relevant antigens
  • Our screening model: focus on specific genes that are clinically relevant for the tumor progression and identify T cell receptors able to recognize neoantigens within those genes

 

10.00
Integrating Non-Mutated and Neoantigens into Highly Personalised Immunotherapy Approaches – Clinical Experiences

  • Norbert Hilf Director of Translational Development, Immatics

Synopsis

  • Reviewing the role of neoantigens and non-mutated antigens in tumors with low mutational burden
  • Understand the GAPVAC approach: concept of actively personalized vaccination in newly diagnosed glioblastoma
  • Analysing final results of the GAPVAC-101 study with a focus on biological activity data
  • Assessing challenges for personalized immunotherapies
  • Going beyond GAPVAC: highly personalized Adoptive Cellular Therapy

10.30
Morning Refreshments & Networking

11.00
Beyond Algorithms: The ATLAS Bioassay Method for Neoantigen Identification & Characterization

Synopsis

  • Assessing how HLA agnostic assay identifies CD4 and CD8 T cell neoantigens
  • Analysing the uniquely distinguished mutations that elicit stimulatory and inhibitory T cell responses
  • Novel updates on clinical development of personalised neoantigen vaccine based on ATLAS platform

Evaluating the Clinical Development of Personalised Cancer Immunotherapy

11.30
Bringing Individualised Neoantigen-based Cancer Vaccines into the Clinic; Challenges, Learnings & Victories

Synopsis

  • Overcoming the hurdles of moving into a new field that challenges standard regulatory guidelines
  • How to meet the demands on lead time, COGS and efficacy for individual vaccines
  • How to deal with the rapid evolvement of combination strategies
  • An update on Vaccibody’s VB N-01 study using personalised vaccines in patients with advanced cancer

12:00
TG Mutant RAS Neoantigen Vaccine: Signal of Clinical Benefit in Resected Pancreatic Cancer

Synopsis

  • Off-the-shelf peptide vaccine targeting a panel of the most frequent oncogenic RAS driver mutations
  • First cancer vaccine to show T-cell responses towards a driver mutation
  • Signal of clinical benefit seen in recently completed phase I/II trial in resected pancreatic cancer

12.30
Lunch & Networking

13.30
Panel Discussion: Global Clinical Development of Neoantigen-based Cancer Therapies

14.30
Induction of Neoantigen-specific T cells with Self-Assembling Nanoparticles

Synopsis

  • Exploring the properties of peptide-based vaccines that impact CD8 T cell induction
  • Evaluating self-assembling nanoparticles as a modular platform for optimising T cell responses
  • Analysing the effect of vaccine dose, route, and TLR-7/8 agonist potency on T cell induction in mice and primates

15.00
Optimising T Cell Response of Neoantigen Cancer Vaccines with Oncolytic Adenoviruses

Synopsis

  • Administration of tumour specific peptides to elicit CD8+ (killer) T-cell responses holds much promise for  treatment of cancer (schematic)
  • Adjuvants such a Poly-IC among others have been tried in combination with peptide Neoantigens, but to date have delivered disappointing efficacy (brief summary)
  • Oncolytic Adenoviruses (OAdV) are highly immunogenic; hence might the combination of Oncolytic AdV (OAdV) with surface peptides solve for the adjuvant issue?
  • Data will be presented that unequivocally shows that OAdV in combination with tumour specific peptides elicit superior CD8+ T cells responses in standard animal models for cancer immunotherapy.

 

15.30
Chair’s Closing Remarks

15.45
Close of 3rd European NeoAg Summit